You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
I’d like to welcome Margaret Manto, who will be reporting on the FDA, and welcome back Nick Florko, who launched this newsletter in 2019, invented STAT’s commercial determinants of health beat, and will be pioneering a new beat covering declining trust in science. Send news tips and tearful reunions to [email protected] or John_Wilkerson.07 on Signal.
GENEROUS deadline approaches for states
States have until Sept. 30 to decide whether to take part in a federal program giving them “most-favored nation” drug prices in Medicaid.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe